Role of MRD Negativity Rates in Treatment Decision Making
Three medical oncologists explore the influence of MRD negativity rates on treatment decisions and discover the ideal patient profile for quadruplet regimen.
EP: 1.PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
EP: 2.Defining Success in Multiple Myeloma Induction and Maintenance
EP: 3.IsKia: Isatuximab Plus KRd in Pre-Transplant Induction and Post-Transplant Consolidation in TE NDMM
Now Viewing
EP: 4.Role of MRD Negativity Rates in Treatment Decision Making
EP: 5.IFM 2018-04: Dara-KRd Induction and Consolidation Plus Double Transplant in HR TE NDMM
EP: 6.Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCT
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
